ArticleActive
Response to Comments: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia
A54893
Effective: June 16, 2016
Updated: December 31, 2025
Policy Summary
No substantive policy text was provided other than the policy ID, title, and a brief description. Extraction could not be completed; obtain the full Noridian response document (MolDX: Genetic Testing for Hypercoagulability/Thrombophilia) to extract indications, limitations, documentation requirements, and frequency limits. Manual review is required.
Coverage Criteria Preview
Key requirements from the full policy
"Source policy content not provided in input; full policy text (Noridian Response to Provider Recommendations for comment period ending 08/10/2015) required to extract documentation requirements and..."
Sign up to see full coverage criteria, indications, and limitations.